Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.53/Share

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q4 EPS of ($0.53), versus ($0.49) reported last year. Revenue for the quarter came in at $600 thousand, versus $400 thousand reported last year.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c